Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Revenue (2016 - 2025)

Historic Revenue for Heron Therapeutics (HRTX) over the last 12 years, with Q3 2025 value amounting to $38.2 million.

  • Heron Therapeutics' Revenue rose 1646.75% to $38.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.1 million, marking a year-over-year increase of 1260.37%. This contributed to the annual value of $144.3 million for FY2024, which is 1357.09% up from last year.
  • Latest data reveals that Heron Therapeutics reported Revenue of $38.2 million as of Q3 2025, which was up 1646.75% from $37.2 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Revenue ranged from a high of $40.8 million in Q4 2024 and a low of $20.0 million during Q1 2021
  • In the last 5 years, Heron Therapeutics' Revenue had a median value of $31.4 million in 2023 and averaged $30.5 million.
  • Its Revenue has fluctuated over the past 5 years, first tumbled by 2118.9% in 2021, then soared by 4537.88% in 2022.
  • Heron Therapeutics' Revenue (Quarter) stood at $20.7 million in 2021, then soared by 45.38% to $30.0 million in 2022, then grew by 14.0% to $34.2 million in 2023, then rose by 19.13% to $40.8 million in 2024, then dropped by 6.3% to $38.2 million in 2025.
  • Its Revenue stands at $38.2 million for Q3 2025, versus $37.2 million for Q2 2025 and $38.9 million for Q1 2025.